29 results on '"Haselkorn T"'
Search Results
2. 49P Epidemiologic study of XL-MTM and clinical expression in the liver (EXCEL): study design of an observational, patient-centric study.
3. PCR-mediated recombination in amplification products derived from polyploid cotton
4. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma.
5. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.
6. P305 REPORTED PRACTICE LOGISTICS FOR IMPLEMENTATION OF SUBCUTANEOUS IMMUNOTHERAPY VERSUS FOOD ORAL IMMUNOTHERAPY AMONG US-BASED ALLERGISTS/IMMUNOLOGISTS.
7. P227 ASTHMA EXACERBATION REDUCTION IN ADULTS WITH HIGH/LOW AIRWAY REVERSIBILITY FOLLOWING OMALIZUMAB TREATMENT: RESULTS FROM PROSPERO.
8. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995.
9. PREDICTORS OF A FUTURE SEVERE ASTHMA EXACERBATION AFTER A DECADE FOLLOW-UP: RESULTS FROM TENOR II.
10. EFFECT OF OMALIZUMAB ON SEASONAL EXACERBATIONS IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA.
11. EFFECTS OF OMALIZUMAB ON MARKERS OF TYPE 2 INFLAMMATION: RESULTS FROM THE EXTRA STUDY.
12. P305 ANCILLARY TREATMENT NEEDS OF PATIENTS RECEIVING ORAL IMMUNOTHERAPY FOR FOOD ALLERGY IN CLINICAL PRACTICE.
13. P226 EFFECT OF OMALIZUMAB IN ASTHMA PATIENTS BY NUMBER OF ASTHMA-RELATED AND ALLERGIC COMORBIDITIES IN PROSPERO.
14. INCREASED INCIDENCE AND PREVALENCE OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS IN THE UNITED STATES.
15. P230 Long-term assessment of the burden of atopic sensitization in patients with severe/difficult-to-treat asthma.
16. P208 Contribution of obesity to disease burden in children with severe or difficult-to-treat asthma.
17. O020 Asthma exacerbations and lung function decline in children during a 52-week controlled trial of omalizumab.
18. O018 Asthma exacerbations and triggers in children with severe/difficult-to-treat asthma: Impact on quality of life.
19. Characterization and Predictors of Asthma Exacerbations in Patients on Steps 4, 5 And 6 Therapy in the TENOR Cohort.
20. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations.
21. Economic burden of impairment in children with severe or difficult-to-treat asthma.
22. Association Between Recent and Future Asthma Exacerbations in Pediatric Patients With Severe or Difficult-to-Treat Asthma.
23. Asthma Control and Risk of Future Asthma Exacerbations: Evaluation of the Impairment Domain of the NHLBI Guidelines in the TENOR Cohort.
24. Relationship Between Asthma Control and Activity Limitation: Insights From the REACT Study.
25. Allergy, Serum IgE, and Lung Function in Children and Adolescents With Severe or Difficult-to-Treat Asthma.
26. Real-World Evaluation of Asthma Control and Treatment (REACT): Findings from a National Web-Based Survey.
27. Demographic and Clinical Characteristics of Children and Adolescents with Severe or Difficult-to-Treat Asthma.
28. Skin testing and IgE levels in patients with severe or difficult-to-treat asthma.
29. 36P Liver involvement in myotubular and centronuclear myopathy: review of one year's data collected by the MTM & CNM Patient Registry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.